‘Opidivo inj. (nivolumab),’ the first cancer immunotherapy approved in Korea has successfully extended its contract ahead termination of its risk-sharing agreement (RSA) term.

In addition to Opdivo, the breast cancer treatment ‘Kisqali (ribosiclib) was also included in the list of drugs that completed negotiations with the National Health Insurance Service (NHIS) that was recently disclosed by NHIS.

The RSA contract term for Opdivo, which was granted reimbursement through the RSA scheme since August 21st, 2017, was set to expire by August 20th this year.

Before expiry, Ono Pharma Korea and Bristol-Myers Squibb Korea Pharmaceutical had applied to the NHIS to exten